The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Orosur Mining drops on disappointing assays

Fri, 02nd Dec 2022 10:40

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Premier Miton Group PLC, up 14% at 104.00 pence, 12-month range 84.69p - 207.00p. Reports both profit and assets under management declined in the year ended September 30. The asset manager posts pretax profit of GBP14.9 million, down 15% from GBP17.5 million a year earlier. Assets under management at September 30 were GBP10.57 billion, down 24% from GBP13.93 billion. More positively, assets under management recover to around GBP11.3 billion at November 25 and the firm sees a return to net positive flows in its funds during the first two months of its current financial year. Chief Executive Mark O'Shea says the results are "resilient" despite tougher market conditions and adds the firm is "well-positioned" to achieve its long-term growth ambitions.

----------

Tern PLC, up 5.0% at 11.03 pence, 12-month range 6.60p - 18.89p. Notes that Device Authority Ltd has expanded its business and technology relationship with an existing "tier one" automotive supply chain customer, winning a contract value of over USD1.2 million over five years. Tern has a 54% stake in the internet of things technology firm. The contract is for the deployment of Device Authority's KeyScaler technology which provides identity management services.

----------

AIM - LOSERS

----------

Orosur Mining Inc, down 31% at 8.78 pence, 12-month range 7.03p - 19.00p. Reports disappointing assay results for four additional diamond holes at the Pepas and Pupino prospects at its Anza project in Colombia. The project is a joint venture with Colombian company Minera Monte Aguila. The assay results indicate the best grade of gold and silver was found at Pepas hole number 009. The results at Pepas 009 show lower levels of gold mineralisation than intersected in previous drilling. No significant results were found at the Pupino prospect. The firm adds it will now shift its focus to groundwork.

----------

ReNeuron Group PLC, down 18% at 18.35 pence, 12-month range 15.00p - 95.22p. Says that it has been investigating an equity raise with investors, but explains "unfavourable conditions" in small-cap equity markets meant this was not possible. Adds that, following a review of its cost base and planned initiatives, savings have been identified in order to extend the firm's cash runway until "at least the start of the fourth calendar quarter of 2023" to ensure the continued development of its technology platform. The stem cell and exosomes technology company also reports a narrowed loss in in the six months ended September 30. Pretax loss totals GBP3.8 million, narrowed from a loss of GBP6.0 million the year before. ReNeuron's revenue multiplies to GBP438,000 from GBP58,000 the year before.

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
23 Oct 2019 09:32

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

Read more
2 Oct 2019 15:15

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

Read more
21 Aug 2019 11:49

ReNeuron boosts scientific advisory board with three appointments

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced the appointment of professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel to its scientific advisory board on Wednesday.

Read more
14 Aug 2019 15:35

ReNeuron's New Cardiff University Venture Gets Research Grant

(Alliance News) - ReNeuron Group PLC on Wednesday said a new venture with Cardiff University has secured a UK government grant to research and develop new treatments for hard-to-target disorders a

Read more
14 Aug 2019 11:16

ReNeuron enters grant-funded partnership with University of Cardiff

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group is partnering with the University of Cardiff under a new grant-funded collaboration utilising its exosome-based drug delivery technology platform, it announced on Wednesday.

Read more
16 Jul 2019 12:16

ReNeuron Secures Patents For Its Exosome Technology Platform

(Alliance News) - ReNeuron Group PLC on Tuesday said it has expanded its intellectual property estate via the grant of patents, covering its exosome technology platform.The cell-based said

Read more
11 Jul 2019 11:36

ReNeuron Annual Loss Narrows On Finance Income And Licence Fee

(Alliance News) - ReNeuron Group PLC on Thursday said its loss narrowed in its most recent financial year after it received an exclusivity fee and increased finance income.Shares in were at

Read more
14 Jun 2019 15:49

ReNeuron wins 'Breakthrough of the Year' at European Mediscience Awards

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has won the 'Breakthrough of the Year' award at the 2019 European Mediscience Awards, it announced on Friday.

Read more
8 May 2019 11:19

ReNeuron Expects Annual Results In Line With Views After Progress

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday said it expects its annual results to be in line with the board's expectations as it made progress on several clinical cell-based also

Read more
8 May 2019 08:53

ReNeuron advances blindness and stroke therapy candidates

(Sharecast News) - Therapeutics outfit ReNeuron continued to trade in line with expectations throughout its recently wrapped up trading year, advancing both its human retinal progenitor cell therapy candidate and its CTX cell therapy candidate.

Read more
26 Apr 2019 12:09

ReNeuron upbeat on early data from retinitis pigmentosa trials

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced updated positive preliminary data in its ongoing phase 1 and 2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP), on Friday.

Read more
26 Apr 2019 09:58

ReNeuron Reports Positive Test Results For Blindness Treatment Therapy

LONDON (Alliance News) - ReNeuron Group PLC on Friday reported positive trial results for its human retinal progenitor cell therapy candidate for treating blindness-causing disease retinitis in up

Read more
11 Apr 2019 18:24

DIRECTOR DEALINGS: ReNeuron Chair And Other Board Members Buy Shares

LONDON (Alliance News) - ReNeuron Group PLC said a number of directors purchased shares on Thursday, including Non-Executive Chair John Berriman who bought 80,000 shares at 225 pence Thursday, in

Read more
9 Apr 2019 10:55

ReNeuron Signs Licence Deal For CTX, hRPC Cell Programmes In China

LONDON (Alliance News) - ReNeuron Group PLC on Tuesday said it has signed an exclusive licence agreement for the development, manufacture and commercialisation of its CTX and hRPC cell therapy in

Read more
4 Apr 2019 14:19

ReNeuron upbeat on progress in hRPC study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on progress with its ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease retinitis pigmentosa (RP) on Thursday, confirming that the positive efficacy seen and previously announced had, to date, been sustained in the first patient cohort in the phase 2 part of the study.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.